Partner Bryan House is quoted in a Society for Human Resource Management article, “Whistle-Blowers Must Report to SEC for Dodd-Frank Retaliation Protection,” about the U.S. Supreme Court’s Feb. 21 ruling that whistle-blower protections under the Dodd-Frank Act do not cover fired employees who do not report alleged securities law violations to the Securities and Exchange Commission.
“All of the justices agreed that the statute’s ‘whistle-blower’ definition is clear and that ends the case,” House said of the decision.
House also said that there has never been any real question about the literal reading of the ‘whistle-blower’ definition in the statute, but that lower courts have “struggled with ‘tension’ between different parts of the statute.”
“All of the justices agreed that the statute’s ‘whistle-blower’ definition is clear and that ends the case,” House said of the decision.
House also said that there has never been any real question about the literal reading of the ‘whistle-blower’ definition in the statute, but that lower courts have “struggled with ‘tension’ between different parts of the statute.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”